{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:08:18Z","timestamp":1788779298267,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01552-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:26:34Z","timestamp":1782462394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Pacitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u2013858.","journal-title":"N Engl J Med"},{"key":"1552_CR2","unstructured":"Diffuse Large B-Cell Lymphoma - Cancer Stat Facts. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. accessed 3 (2026)."},{"key":"1552_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u2013363.","journal-title":"N Engl J Med"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO-25-00925","volume":"43","author":"F Morschhauser","year":"2025","unstructured":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M, et al. Five-year outcomes of the POLARIX study comparing pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol. 2025;43:3698\u20133705.","journal-title":"J Clin Oncol"},{"key":"1552_CR6","doi-asserted-by":"crossref","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F, De Leval L, Dreyling M, Eichenauer DA, et al. Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:1263\u201384.","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"1552_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)- B-Cell Lymphomas Ver. 3.2026. National Comprehensive Cancer Network., https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (2026)."},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339:21\u201326.","journal-title":"N Engl J Med"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"M Pfeifer","year":"2015","unstructured":"Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29:1578\u20131586.","journal-title":"Leukemia"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Polatuzumab vedotin: first global approval. Drugs. 2019;79:1467\u20131475.","journal-title":"Drugs"},{"key":"1552_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104611","volume":"207","author":"HA Farooqi","year":"2025","unstructured":"Farooqi HA, Saffi Ullah M, Raza A, Sadiq Z, Shaikh WA, Muhammad R, et al. Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;207:104611.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1158\/1078-0432.CCR-24-1729","volume":"30","author":"M Sarraf Yazdy","year":"2024","unstructured":"Sarraf Yazdy M, Kasamon YL, Gu W, Rodriguez LR, Jin S, Bhatnagar V, et al. FDA approval summary: polatuzumab vedotin in the first-line treatment of select large B-cell lymphomas. Clin Cancer Res. 2024;30:5521\u20135526.","journal-title":"Clin Cancer Res"},{"key":"1552_CR13","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"e2025070","DOI":"10.4084\/MJHID.2025.070","volume":"17","author":"S Sato","year":"2025","unstructured":"Sato S, Sawazaki E, Tsunoda S, Kamata W, Togano T, Tamai Y. Dose-attenuated-polatuzumab vedotine plus CHP vs. dose-attenuated -R-CHOP in patients aged \u2265 80 years with diffuse large B-cell lymphoma: a retrospective, propensity score-matched analysis stratified by simplified frailty score. Mediterr J Hematol Infect Dis. 2025;17:e2025070.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"7822","DOI":"10.1182\/blood-2024-205048","volume":"144","author":"Y Sekiguchi","year":"2024","unstructured":"Sekiguchi Y, Tsutsumi H, Kudou M, Maseki N, Iizaki Y, Kobayashi K, et al. Efficacy and safety of R-Mini-CHP administered in combination with polatuzumab vedotin (Pola-R-mini-CHP) in patients \u226580 years old with diffuse large B-cell lymphoma in the real-world setting: a single-institute retrospective study. Blood. 2024;144:7822.","journal-title":"Blood"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1007\/s00277-025-06619-0","volume":"104","author":"T Yamada","year":"2025","unstructured":"Yamada T, Nakamura N, Goto H, Hara T, Kasahara S, Fukuno K, et al. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study. Ann Hematol. 2025;104:5191\u20135200.","journal-title":"Ann Hematol"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139\u2013145.","journal-title":"Contemp Clin Trials"},{"key":"1552_CR18","unstructured":"JASP Team. JASP (Version 0.95.4) [Computer software]. https:\/\/jasp-stats.org\/ (2025)."},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023;141:1971\u20131981.","journal-title":"Blood"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/bloodadvances.2024014907","volume":"9","author":"J Westin","year":"2025","unstructured":"Westin J, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, et al. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025;9:2461\u20132472.","journal-title":"Blood Adv"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1007\/s00277-025-06526-4","volume":"104","author":"Y Ren","year":"2025","unstructured":"Ren Y, Cheng L, Zhuang J, Wang Z, Yuan L, Cheng Z, et al. Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients: Article type: research. Ann Hematol. 2025;104:4165\u20134173.","journal-title":"Ann Hematol"},{"key":"1552_CR22","doi-asserted-by":"crossref","unstructured":"Wang Z, Wei C, Shen K-N, Cai H, Zhao D, Zhou D, et al. Real-world comparative analysis of polatuzumab vedotin-based polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone versus standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma: a propensity score-matched cohort study. Oncology. 2025;20:1\u201313.","DOI":"10.1159\/000549477"},{"key":"1552_CR23","doi-asserted-by":"crossref","unstructured":"Terao T, Yoshida I, Kobayashi H, Urata T, Fujii F, Meguri Y, et al. Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: a multicentre real-world study. Br J Haematol. 2026;208:554\u2013563.","DOI":"10.1111\/bjh.70280"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2024-202741","volume":"144","author":"V Iyengar","year":"2024","unstructured":"Iyengar V, Chicola J, Joseph A, Okwali M, Truong R, Bapodra N, et al. Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Blood. 2024;144:2336.","journal-title":"Blood"},{"key":"1552_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70017","volume":"43","author":"P Zhao","year":"2025","unstructured":"Zhao P, Zhao S, Huang C, Li Y, Wang J, Xu J, et al. Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: a real-world, multi-center, retrospective cohort study. Hematological Oncology. 2025;43:e70017.","journal-title":"Hematological Oncology"},{"key":"1552_CR26","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood-2025-4486","volume":"146","author":"M Matasar","year":"2025","unstructured":"Matasar M, Masaquel A, Reyes C, Hossain F, Zuk E, Straubing R, et al. Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States. Blood. 2025;146:4486.","journal-title":"Blood"},{"key":"1552_CR27","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1002\/hon.70094_289","volume":"43","author":"SK Thiruvengadam","year":"2025","unstructured":"Thiruvengadam SK, Chen L, Buller S, Iyengar V, Pelaez G, Pizzuti V, et al. 289 | Multicenter real-world outcomes of frontline Pola-R-Chp in treatment na\u00efve Dlbcl. Hematol Oncol. 2025;43:e289\u201370094.","journal-title":"Hematol Oncol"},{"key":"1552_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2025-784","volume":"146","author":"V Iyengar","year":"2025","unstructured":"Iyengar V, Meeko Manzano J, Chen L, Chicola J, Okwali M, Buller S, et al. Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma. Blood. 2025;146:784.","journal-title":"Blood"},{"key":"1552_CR29","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1182\/blood-2025-6265","volume":"146","author":"P Reagan","year":"2025","unstructured":"Reagan P, Shamas N, Masaquel A, Hossain F, Sa A, Li S, et al. Patient characteristics and treatment outcomes with Pola-R-CHP: a real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US). Blood. 2025;146:6265.","journal-title":"Blood"},{"key":"1552_CR30","doi-asserted-by":"crossref","unstructured":"Scheffer Cliff ER, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K et al. Cell-of-origin subtype predicts response to polatuzumab vedotin in large b cell lymphoma. Clin Cancer Res. 2026;32:159\u2013168.","DOI":"10.1158\/1078-0432.CCR-25-2392"},{"key":"1552_CR31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2025-1913","volume":"146","author":"G Tumyan","year":"2025","unstructured":"Tumyan G, Semenova A, Ermakova Y, Chuprakova A, Chernova A, Frolova M, et al. Pola-R-CHP in previously untreated diffuse large B-cell lymphoma: Real-world data in Russia. Blood. 2025;146:1913.","journal-title":"Blood"},{"key":"1552_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116624","volume":"474","author":"S Frachet","year":"2023","unstructured":"Frachet S, Danigo A, Duchesne M, Richard L, Sturtz F, Magy L, et al. A mouse model of sensory neuropathy induced by a long course of monomethyl-auristatin E treatment. Toxicol Appl Pharmacol. 2023;474:116624.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1552_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ren X, Dai Y, Wang Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Sci Rep. 2024;14:21386.","journal-title":"Sci Rep"},{"key":"1552_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10552-015-0610-8","volume":"26","author":"AJ Olszewski","year":"2015","unstructured":"Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26:1163\u20131172.","journal-title":"Cancer Causes Control"},{"key":"1552_CR35","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354\u20132361.","journal-title":"Blood"},{"key":"1552_CR36","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848\u20132856.","journal-title":"J Clin Oncol"},{"key":"1552_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u2013282.","journal-title":"Blood"},{"key":"1552_CR38","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489\u20132496.","journal-title":"Blood"},{"key":"1552_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood.2023023789","volume":"145","author":"D Qualls","year":"2025","unstructured":"Qualls D, Armand P, Salles G. The current landscape of frontline large B-cell lymphoma trials. Blood. 2025;145:176\u2013189.","journal-title":"Blood"},{"key":"1552_CR40","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/10428194.2020.1869228","volume":"62","author":"H-JJ Cherng","year":"2021","unstructured":"Cherng H-JJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62:1302\u20131312.","journal-title":"Leuk Lymphoma"},{"key":"1552_CR41","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-Cell Lymphoma. J Clin Oncol. 2021;39:1317\u20131328.","journal-title":"J Clin Oncol"},{"key":"1552_CR42","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285\u20131295.","journal-title":"J Clin Oncol"},{"key":"1552_CR43","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.23.00033","volume":"41","author":"AJ Davies","year":"2023","unstructured":"Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al. Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up. J Clin Oncol. 2023;41:2718\u20132723.","journal-title":"J Clin Oncol"},{"key":"1552_CR44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2306105","volume":"389","author":"AC Palmer","year":"2023","unstructured":"Palmer AC, Kurtz DM, Alizadeh AA. Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin. N Engl J Med. 2023;389:764\u2013766.","journal-title":"N Engl J Med"},{"key":"1552_CR45","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1182\/blood.2022016624","volume":"140","author":"SK Thiruvengadam","year":"2022","unstructured":"Thiruvengadam SK, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, et al. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022;140:2697\u20132708.","journal-title":"Blood"},{"key":"1552_CR46","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1182\/blood.2022017342","volume":"140","author":"ER Scheffer Cliff","year":"2022","unstructured":"Scheffer Cliff ER, Pandya A. Pola-R-CHP for DLBCL: cost-effective at first glance. Blood. 2022;140:2654\u20132655.","journal-title":"Blood"},{"key":"1552_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15477-9","volume":"15","author":"M Li","year":"2025","unstructured":"Li M, Li Q, Zhang Y, Xu C, Chen Z, Huang Y, et al. Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China. Sci Rep. 2025;15:29752.","journal-title":"Sci Rep"},{"key":"1552_CR48","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1182\/blood.2023022048","volume":"142","author":"DA Russler-Germain","year":"2023","unstructured":"Russler-Germain DA, Cliff ERS, Bartlett NL. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis. Blood. 2023;142:2216\u20132219.","journal-title":"Blood"},{"key":"1552_CR49","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675\u20131684.","journal-title":"Blood"},{"key":"1552_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u2013654.","journal-title":"N Engl J Med"},{"key":"1552_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/17474086.2022.2044778","volume":"15","author":"S Perrone","year":"2022","unstructured":"Perrone S, Lopedote P, Levis M, Di Rocco A, Smith SD. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. Expert Rev Hematol. 2022;15:215\u2013232.","journal-title":"Expert Rev Hematol"},{"key":"1552_CR52","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M, Huang H-Q, Fox CP, Zhang H, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404:1940\u20131954.","journal-title":"Lancet"},{"key":"1552_CR53","doi-asserted-by":"crossref","unstructured":"Lenz G, Trn\u011bn\u00fd M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407:2528\u20132541.","DOI":"10.1016\/S0140-6736(26)00866-4"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01552-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:12:26Z","timestamp":1788775946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01552-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01552-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SF is a consultant for Janssen, EUSA Pharma, AbbVie, and Sandoz; is on the advisory board of Janssen, EUSA Pharma, Recordati, Incyte, Roche, AstraZeneca, Italfarmaco, and Behring; received speaker\u2019s honoraria from Janssen, EUSA Pharma, Recordati, Lilly, Beigene, Gilead, and Gentili; and received research funding from Gilead and Morphosys. No other conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"149"}}